Lung cancer can be treated effectively by surgery if it is identified as early stage, but even early-stage cancer may not be suitable for surgical removal if patients are at higher risk with conditions such as heart disease, diabetes, or lung disease. Lung cancer is particularly common among the elderly, who tend to have a higher rate of comorbidities making surgery difficult in many cases. In many cases, treatment and management of these comorbidities can reduce the risk to the point at which surgery is feasible, but cancer hospitals are generally unable to provide this sort of care, meaning that it is often impossible for them to provide adequate treatment for lung cancer. To make surgery less invasive, it is also necessary to carry out more difficult procedures in a safe manner.
Dr. Kenji Suzuki, Professor of the Department of General Thoracic Surgery at our hospital is one of the world’s most renowned lung cancer surgeons. Particularly for early-stage lung cancer, he has actively introduced minimally invasive, restricted surgery that conserves as much lung tissue as possible in order to maintain postoperative lung function, achieving extremely impressive results: a 5-year survival rate of 95%, and a complication rate about one-fifth that of leading Western institutions. High-risk lung cancer patients, such as the elderly and individuals with comorbidities, can undergo safe and effective surgery while their comorbidities are treated and their general condition managed in collaboration with the Department of Respiratory Medicine, which is led by Professor Kazuhisa Takahashi.
The general use of CT to diagnose lung cancer in Japan and the wealth of experience in its use means that definitive diagnosis is outstanding in global terms. At our hospital, we use helical CT to identify even tiny lung cancers in the early stages, and utilize minimally invasive, restricted surgery in the endeavor to achieve complete cure while preserving maximum lung function.
Juntendo, founded in 1838, was the first educational institution to teach Western medicine in Japan in combination with medical institutions, and boasts a long history and tradition dating back over 170 years. It has achieved numerous successes, not only in the clinical sphere, but also in research into cutting-edge treatments.
As one of the largest centers for the treatment of lung cancer in Japan, Juntendo treats over 600 patients a year in the Departments of Respiratory Medicine and General Thoracic Surgery. These departments work in close collaboration to function as a “Respiratory Center,” enabling selection of the optimum treatment strategy for each patient from among a wide range of options.
The Department of General Thoracic Surgery is one of the few departments worldwide to perform procedures ranging from extended surgery to minimally invasive thoracoscopic surgery on a daily basis, and based on this wealth of experience, the department is maintaining excellent results while increasingly making use of minimally invasive techniques. The Department of Respiratory Medicine not only offers the latest chemotherapy and immunotherapy for advanced cancers, but is also promoting the use of individually tailored therapies, including molecular-targeted drugs. The department also has some of the best results in Japan for the treatment of other lung diseases such as chronic obstructive pulmonary disease (COPD) and interstitial pneumonia, and in many cases lung cancer patients with other respiratory diseases or complications are also able to undergo surgery. In addition, excellent collaboration with other departments also enables the Department to offer the best possible treatment for lung cancer patients who are unable to undergo surgery due to other disorders such as cerebral infarction, myocardial infarction, angina, kidney failure, or chronic hepatitis.
One feature of cancer treatment at our center is that sophisticated surgical procedures can be combined with high-level chemotherapy and radiotherapy. Even lung cancer patients who have been told by other hospitals that their old age and comorbidities mean surgery is impossible may be able to undergo surgery in our center using minimally invasive techniques and treatment for their comorbidities, so please feel free to consult us. Not only our doctors but all our other medical staff work together as a single team to treat each individual patient, which both improves our therapeutic results and increases the level of patient satisfaction. Most of our staff can communicate in English, and we hope this will help set your mind at ease in the choice to undergo treatment with us.
Dr. Kenji Suzuki
Professor of the Department of General Thoracic Surgery
Dr. Kazuhisa Takahashi
Professor of the Department of Respiratory Medicine
We need information on the previous clinical course and diagnostic imaging data of the patient (X-rays and CTs, and if possible PET images) in advance when arranging to undergo treatment. Pathological specimens are also very helpful, if available. A definitive diagnosis can be undertaken after arriving in Japan.
|External View of Our Hospital||Dr. Suzuki During Surgery|
Department of Respiratory Medicine 1969
Department of General Thoracic Surgery 2002
(Juntendo was founded in 1838)
Respiratory Medicine, General Thoracic Surgery
Cash, Credit Card (Diners Club, VISA, MasterCard), Debit Card
3-3-3 Hongo, Bunkyo-ku, Tokyo 113-8431
|Approximately 5 minutes on foot
from the JR Ochanomizu Station
Approximately 5 minutes on foot
from Tokyo Metro Ochanomizu Station
Approximately 7 minutes on foot
from Tokyo Metro Shin-ochanomizu Station
|Approximately 30 minutes from
Tokyo International Airport (Haneda Airport) by car